Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q4 2015 · 10-K
Revenue—
Net Income-$4.52M-$4.52MN/M vs Q4 2014 EPS Diluted-$0.10-$0.10N/M vs Q4 2014 Operating Incomederived-$4,534,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Operating Cash Flowderived
Free Cash Flowderived-$3,548,000N/M ended Dec 31, 2015 · filed Mar 3, 2016 · 63 d after period end